Nasdaq: $28.17 (+0.04) | AIM: £3.86 (-0.26)
News & Presentations
Previous Article   |   Next Article
Presentations, Scientific Publications | 17 Oct 2017

WCLC 2017: Phase Ib/II savolitinib plus Iressa® in MET-driven NSCLC

OA 09.06 – A Phase Ib Trial of Savolitinib plus Gefitinib for Chinese Patients with EGFR-Mutant MET-Amplified Advanced NSCLC

Jin-Ji Yang, Jian Fang, Y. Shu, J. Chang, G. Chen, J. He, W. Li, X. Liu, N. Yang, Caicun Zhou, J. Huang, L. Yang, A.A. Handzel, M.M. Frigault, G. Ahmed, C. Egile, S. Morgan, Yi-Long Wu

Venue: IASLC 18th World Conference on Lung Cancer
Session: OA 09 – EGFR TKI Resistance (ID 663)
Presenter: Jin-Ji Yang
Date: Tuesday, October 17, 2017

For a summary of the data presented, please see the company overview presentation.